Methylphenidate: yearly treatment review advised

Updated guidance from the MHRA advises that treatment with methylphenidate should be interrupted at least yearly to determine whether continued use is necessary.

The MHRA has also reminded healthcare professionals of the need to screen and monitor patients for psychiatric and cardiovascular symptoms before and during treatment with the stimulant.

 

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

New secondary prevention approach backed for patients with stable cardiovascular disease

New secondary prevention approach backed for patients with stable cardiovascular disease

NHS prescribers have a new routine option for preventing...

Asthma and COPD Preparations and Compatible Devices

Asthma and COPD Preparations and Compatible Devices

Available presentations of bronchodilators and anti-inflammatories.

Ranitidine in short supply after contamination fears prompt precautionary recall

Ranitidine in short supply after contamination fears prompt precautionary recall

GPs have reported shortages of ranitidine following...

Drug shortages - live tracker

Drug shortages - live tracker

Added: Alzhok and ranitidine oral soln.
Use our...